Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • The Pharma 50

REGEN-COV cuts viral load within 7 days in COVID-19 patients

By Brian Buntz | September 30, 2021

Regeneron-RocheRegeneron Pharmaceuticals (NSDQ:REGN) and Roche (OTCQX: RHHBY) are touting positive results from a Phase 2/3 study investigating the potential of REGEN-COV (casirivimab and imdevimab) antibody cocktail in hospitalized COVID-19 patients.
The study met its primary endpoint of reducing viral load within one week in seronegative patients needing low-flow or no supplemental oxygen.

REGEN-COV, known as Ronapreve outside of the U.S., led to a 36% reduced risk of death by day 29 in the overall treatment population.

“These new results, combined with the nearly 10,000-patient RECOVERY trial, further validate how REGEN-COV can change the course of illness for patients even after they are hospitalized with COVID-19,” said Dr. George D. Yancopoulos, president and chief scientific officer at Regeneron, in a statement.

Roche has partnered with Regeneron (NSDQ: REGN) to help manufacture and distribute REGN-COV2, which Regeneron first developed.

Roche’s chief medical officer, Dr. Levi Garraway, said the results indicate that the cocktail of casirivimab and imdevimab could “help to ease pressure on healthcare systems.”

The New England Journal of Medicine also published recent data on casirivimab and imdevimab in patients with severe COVID-19 infections.

The separate UK RECOVERY study came to similar conclusions, finding meaningful benefit for patients who received 2,400-mg or 8,000-mg doses of Ronapreve plus standard of care.

 


Filed Under: clinical trials, Drug Discovery, Infectious Disease, Uncategorized
Tagged With: Casirivimab, covid-19, COVID-19 antibody treatment, Imdevimab, REGEN-COV, Regeneron, Regeneron Pharmaceuticals, Roche, Roche Group, Ronapreve
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

Trikafta wins Canadian approval for Trikafta in children with cystic fibrosis
Moderna
Moderna seeks FDA blessing for second COVID-19 vaccine booster
Novartis
Novartis partners with Carisma Therapeutics on manufacturing HER2-targeted CAR-M cell therapy
Medicago and GSK
Medicago and GSK win approval from Health Canada for adjuvanted plant-based COVID-19 vaccine

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • The Pharma 50